NewsBlazeIN – Lifestyle
Author:
Sitryx Therapeutics
First-in-Class Oral PKM2 Modulator SYX-5219 Phase 1a Trial Data to be Presented at SID 2026
May 13, 2026
Sitryx nominates novel, oral GLS1 inhibitor for clinical development in moderate to severe asthma
April 2, 2026
Sitryx to participate in upcoming April investor conferences
March 26, 2026